FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.
|Articles|August 9, 2022
BioNTech Says Variant COVID-19 Vaccines May Be Available as Early as October
Author(s)John Parkinson
The company and its partner, Pfizer, are preparing for the potential launch of 2 variant-adapted bivalent COVID-19 vaccines assuming authorizations from FDA and EMA.
Advertisement
During its most recent quarterly earnings report yesterday, BioNTech said it was looking at a potential launch of COVID-19 vaccines this fall pending regulatory approval.
“Our COVID-19 product pipeline includes variant-adapted and next-generation vaccine candidates, aimed at prolonged and broad protection,” Ugur Sahin, MD, CEO and Co-Founder of BioNTech, said in a prepared statement.
The companies are looking at 2 variant-adapted bivalent COVID-19 vaccines containing the original strain and Omicron BA.1 or BA.4/5 spike protein.
In recent weeks, the companies announced they had begun a phase 2 trial looking at a new vaccine candidate, BNT162b5, at a 30 µg dose level in a randomized, active-controlled, observer-blind study.
Pfizer-BioNTech are calling the candidate a next-generation bivalent COVID-19 vaccine that has RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
The study is being conducted in the United States and looks to enroll approximately 200 participants between 18 and 55 years of age and who have received 1 booster dose of a US-authorized COVID-19 vaccine at least 90 days prior to their first study visit.
Advertisement
Related to this article
The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.
The death was reported in Jefferson County where the coroner released a statement announcing it was in an unvaccinated woman.
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
The antiviral did not produce greater symptom improvement than placebo in patients with the condition in the RECOVER-VITAL trial.
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.
Advertisement
Advertisement
Trending on Contagion Live
1
Measles Update: September 25, 2026
2
US Company Recalls Thousands of Pounds of Uninspected Meat
3
Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions
4
How The Food Safety Surveillance Infrastructure Works in the US
5